Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 141

1.

Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1 c259T Cells in Synovial Sarcoma.

D'Angelo SP, Melchiori L, Merchant MS, Bernstein D, Glod J, Kaplan R, Grupp S, Tap WD, Chagin K, Binder GK, Basu S, Lowther DE, Wang R, Bath N, Tipping A, Betts G, Ramachandran I, Navenot JM, Zhang H, Wells DK, Van Winkle E, Kari G, Trivedi T, Holdich T, Pandite L, Amado R, Mackall CL.

Cancer Discov. 2018 Aug;8(8):944-957. doi: 10.1158/2159-8290.CD-17-1417. Epub 2018 Jun 11.

PMID:
29891538
2.

Fludarabine and neurotoxicity in engineered T-cell therapy.

Lowe KL, Mackall CL, Norry E, Amado R, Jakobsen BK, Binder G.

Gene Ther. 2018 Jun;25(3):176-191. doi: 10.1038/s41434-018-0019-6. Epub 2018 May 7.

PMID:
29789639
3.

Tiered application of the neutral red release and EpiOcular™ assays for evaluating the eye irritation potential of agrochemical formulations.

Settivari RS, Amado RA, Corvaro M, Visconti NR, Kan L, Carney EW, Boverhof DR, Gehen SC.

Regul Toxicol Pharmacol. 2016 Nov;81:407-420. doi: 10.1016/j.yrtph.2016.09.028. Epub 2016 Sep 28.

PMID:
27693708
4.

Application of the KeratinoSens™ assay for assessing the skin sensitization potential of agrochemical active ingredients and formulations.

Settivari RS, Gehen SC, Amado RA, Visconti NR, Boverhof DR, Carney EW.

Regul Toxicol Pharmacol. 2015 Jul;72(2):350-60. doi: 10.1016/j.yrtph.2015.05.006. Epub 2015 May 14.

PMID:
25981449
5.

Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma.

Suttle AB, Ball HA, Molimard M, Hutson TE, Carpenter C, Rajagopalan D, Lin Y, Swann S, Amado R, Pandite L.

Br J Cancer. 2014 Nov 11;111(10):1909-16. doi: 10.1038/bjc.2014.503. Epub 2014 Oct 28. Erratum in: Br J Cancer. 2014 Dec 9;111(12):2383.

6.

Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials.

Tran HT, Liu Y, Zurita AJ, Lin Y, Baker-Neblett KL, Martin AM, Figlin RA, Hutson TE, Sternberg CN, Amado RG, Pandite LN, Heymach JV.

Lancet Oncol. 2012 Aug;13(8):827-37. doi: 10.1016/S1470-2045(12)70241-3. Epub 2012 Jul 2.

PMID:
22759480
7.

Transarterial chemoembolization plus or minus intravenous bevacizumab in the treatment of hepatocellular cancer: a pilot study.

Britten CD, Gomes AS, Wainberg ZA, Elashoff D, Amado R, Xin Y, Busuttil RW, Slamon DJ, Finn RS.

BMC Cancer. 2012 Jan 14;12:16. doi: 10.1186/1471-2407-12-16.

8.

Predictive genomic biomarkers.

Kumar R, Amado RG.

Curr Top Microbiol Immunol. 2012;355:173-88. doi: 10.1007/82_2011_164. Review.

PMID:
21877260
9.

Triple-drug transcatheter arterial chemoembolization in unresectable hepatocellular carcinoma: assessment of survival in 124 consecutive patients.

Gomes AS, Rosove MH, Rosen PJ, Amado RG, Sayre JW, Monteleone PA, Busuttil RW.

AJR Am J Roentgenol. 2009 Dec;193(6):1665-71. doi: 10.2214/AJR.08.1806.

PMID:
19933662
10.

An open-label clinical trial evaluating safety and pharmacokinetics of two dosing schedules of panitumumab in patients with solid tumors.

Stephenson JJ, Gregory C, Burris H, Larson T, Verma U, Cohn A, Crawford J, Cohen RB, Martin J, Lum P, Yang X, Amado RG.

Clin Colorectal Cancer. 2009 Jan;8(1):29-37. doi: 10.3816/CCC.2009.n.005.

PMID:
19203894
11.

Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy.

Peeters M, Siena S, Van Cutsem E, Sobrero A, Hendlisz A, Cascinu S, Kalofonos H, Devercelli G, Wolf M, Amado RG.

Cancer. 2009 Apr 1;115(7):1544-54. doi: 10.1002/cncr.24088.

12.

A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer.

Hecht JR, Mitchell E, Chidiac T, Scroggin C, Hagenstad C, Spigel D, Marshall J, Cohn A, McCollum D, Stella P, Deeter R, Shahin S, Amado RG.

J Clin Oncol. 2009 Feb 10;27(5):672-80. doi: 10.1200/JCO.2008.19.8135. Epub 2008 Dec 29.

PMID:
19114685
13.

Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone.

Freeman DJ, Juan T, Reiner M, Hecht JR, Meropol NJ, Berlin J, Mitchell E, Sarosi I, Radinsky R, Amado RG.

Clin Colorectal Cancer. 2008 May;7(3):184-90. doi: 10.3816/CCC.2008.n.024.

PMID:
18621636
14.

Targeting vascular endothelial growth factor with the monoclonal antibody bevacizumab inhibits human hepatocellular carcinoma cells growing in an orthotopic mouse model.

Finn RS, Bentley G, Britten CD, Amado R, Busuttil RW.

Liver Int. 2009 Feb;29(2):284-90. doi: 10.1111/j.1478-3231.2008.01762.x. Epub 2008 May 14.

PMID:
18482274
15.

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.

Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD, Chang DD.

J Clin Oncol. 2008 Apr 1;26(10):1626-34. doi: 10.1200/JCO.2007.14.7116. Epub 2008 Mar 3.

16.

Dose and schedule study of panitumumab monotherapy in patients with advanced solid malignancies.

Weiner LM, Belldegrun AS, Crawford J, Tolcher AW, Lockbaum P, Arends RH, Navale L, Amado RG, Schwab G, Figlin RA.

Clin Cancer Res. 2008 Jan 15;14(2):502-8. doi: 10.1158/1078-0432.CCR-07-1509.

17.

Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab.

Siena S, Peeters M, Van Cutsem E, Humblet Y, Conte P, Bajetta E, Comandini D, Bodoky G, Van Hazel G, Salek T, Wolf M, Devercelli G, Woolley M, Amado RG.

Br J Cancer. 2007 Dec 3;97(11):1469-74. Epub 2007 Nov 27.

18.

Influence of roasting conditions on the acrylamide content and the color of roasted almonds.

Lukac H, Amrein TM, Perren R, Conde-Petit B, Amadò R, Escher F.

J Food Sci. 2007 Jan;72(1):C033-8.

PMID:
17995869
19.

From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice.

Jakobovits A, Amado RG, Yang X, Roskos L, Schwab G.

Nat Biotechnol. 2007 Oct;25(10):1134-43.

PMID:
17921999
20.

Occurrence of acrylamide in selected foods and mitigation options.

Amrein TM, Andres L, Escher F, Amadò R.

Food Addit Contam. 2007;24 Suppl 1:13-25. Review.

PMID:
17687696
21.

An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy.

Van Cutsem E, Siena S, Humblet Y, Canon JL, Maurel J, Bajetta E, Neyns B, Kotasek D, Santoro A, Scheithauer W, Spadafora S, Amado RG, Hogan N, Peeters M.

Ann Oncol. 2008 Jan;19(1):92-8. Epub 2007 Sep 4.

PMID:
17785764
22.

Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer.

Hecht JR, Patnaik A, Berlin J, Venook A, Malik I, Tchekmedyian S, Navale L, Amado RG, Meropol NJ.

Cancer. 2007 Sep 1;110(5):980-8.

23.

Fermentation of resistant starches: influence of in vitro models on colon carcinogenesis.

Fässler C, Gill CI, Arrigoni E, Rowland I, Amadò R.

Nutr Cancer. 2007;58(1):85-92.

PMID:
17571971
24.

Panitumumab with irinotecan/leucovorin/5-fluorouracil for first-line treatment of metastatic colorectal cancer.

Berlin J, Posey J, Tchekmedyian S, Hu E, Chan D, Malik I, Yang L, Amado RG, Hecht JR.

Clin Colorectal Cancer. 2007 Mar;6(6):427-32.

PMID:
17531105
25.

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.

Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, Canon JL, Van Laethem JL, Maurel J, Richardson G, Wolf M, Amado RG.

J Clin Oncol. 2007 May 1;25(13):1658-64.

PMID:
17470858
26.

Physiological and metabolic properties of a digestion-resistant maltodextrin, classified as type 3 retrograded resistant starch.

Brouns F, Arrigoni E, Langkilde AM, Verkooijen I, Fässler C, Andersson H, Kettlitz B, van Nieuwenhoven M, Philipsson H, Amado R.

J Agric Food Chem. 2007 Feb 21;55(4):1574-81. Epub 2007 Jan 25.

PMID:
17253707
27.

Investigations on the promoting effect of ammonium hydrogencarbonate on the formation of acrylamide in model systems.

Amrein TM, Andres L, Manzardo GG, Amado R.

J Agric Food Chem. 2006 Dec 27;54(26):10253-61.

PMID:
17177568
28.

Human faecal microbiota develops the ability to degrade type 3 resistant starch during weaning.

Scheiwiller J, Arrigoni E, Brouns F, Amadò R.

J Pediatr Gastroenterol Nutr. 2006 Nov;43(5):584-91.

PMID:
17130732
29.

In vitro fermentability of differently digested resistant starch preparations.

Fässler C, Arrigoni E, Venema K, Brouns F, Amadò R.

Mol Nutr Food Res. 2006 Dec;50(12):1220-8.

PMID:
17103375
30.

Digestibility of resistant starch containing preparations using two in vitro models.

Fässler C, Arrigoni E, Venema K, Hafner V, Brouns F, Amadò R.

Eur J Nutr. 2006 Dec;45(8):445-53. Epub 2006 Oct 11.

31.

Authentication of the botanical and geographical origin of honey by mid-infrared spectroscopy.

Ruoff K, Luginbühl W, Künzli R, Iglesias MT, Bogdanov S, Bosset JO, von der Ohe K, von der Ohe W, Amado R.

J Agric Food Chem. 2006 Sep 6;54(18):6873-80.

PMID:
16939352
32.

Authentication of the botanical origin of honey by near-infrared spectroscopy.

Ruoff K, Luginbühl W, Bogdanov S, Bosset JO, Estermann B, Ziolko T, Amado R.

J Agric Food Chem. 2006 Sep 6;54(18):6867-72.

PMID:
16939351
33.

Authentication of the botanical and geographical origin of honey by front-face fluorescence spectroscopy.

Ruoff K, Luginbühl W, Künzli R, Bogdanov S, Bosset JO, von der Ohe K, von der Ohe W, Amado R.

J Agric Food Chem. 2006 Sep 6;54(18):6858-66.

PMID:
16939350
34.

Influence of thermal processing conditions on acrylamide generation and browning in a potato model system.

Amrein TM, Limacher A, Conde-Petit B, Amado R, Escher F.

J Agric Food Chem. 2006 Aug 9;54(16):5910-6.

PMID:
16881694
35.

Randomized, double-blind, active-controlled trial of every-3-week darbepoetin alfa for the treatment of chemotherapy-induced anemia.

Canon JL, Vansteenkiste J, Bodoky G, Mateos MV, Bastit L, Ferreira I, Rossi G, Amado RG.

J Natl Cancer Inst. 2006 Feb 15;98(4):273-84.

PMID:
16478746
36.

Factors influencing acrylamide formation in gingerbread.

Amrein TM, Schönbächler B, Escher F, Amadò R.

Adv Exp Med Biol. 2005;561:431-46.

PMID:
16438317
37.

Human gut microbiota does not ferment erythritol.

Arrigoni E, Brouns F, Amadò R.

Br J Nutr. 2005 Nov;94(5):643-6.

PMID:
16277764
38.
39.

Acrylamide in roasted almonds and hazelnuts.

Amrein TM, Lukac H, Andres L, Perren R, Escher F, Amadò R.

J Agric Food Chem. 2005 Oct 5;53(20):7819-25.

PMID:
16190636
40.

A randomized, multicenter study of subcutaneous and intravenous darbepoetin alfa for the treatment of chemotherapy-induced anemia.

Justice G, Kessler JF, Jadeja J, Campos L, Weick J, Chen CF, Heatherington AC, Amado RG.

Ann Oncol. 2005 Jul;16(7):1192-8. Epub 2005 Apr 28.

PMID:
15860486
41.

Authentication of the botanical origin of honey by front-face fluorescence spectroscopy. A preliminary study.

Ruoff K, Karoui R, Dufour E, Luginbühl W, Bosset JO, Bogdanov S, Amado R.

J Agric Food Chem. 2005 Mar 9;53(5):1343-7.

PMID:
15740004
42.

Radiofrequency ablation of hepatocellular carcinoma: treatment success as defined by histologic examination of the explanted liver.

Lu DS, Yu NC, Raman SS, Limanond P, Lassman C, Murray K, Tong MJ, Amado RG, Busuttil RW.

Radiology. 2005 Mar;234(3):954-60. Epub 2005 Jan 28.

PMID:
15681691
43.

[Validation of a health survey questionnaire focusing on risk factors for coronary artery disease in a group of public employees in Juiz de Fora, Minas Gerais State, Brazil].

Bittencourt RJ, Chaves SR, Amado RC, Mendonça VF, de Oliveira FJ, Antunes CM.

Cad Saude Publica. 2004 May-Jun;20(3):761-70. Epub 2004 May 19. Portuguese.

44.

Acrylamide in gingerbread: critical factors for formation and possible ways for reduction.

Amrein TM, Schönbächler B, Escher F, Amado R.

J Agric Food Chem. 2004 Jun 30;52(13):4282-8.

PMID:
15212481
45.

Anti-human immunodeficiency virus hematopoietic progenitor cell-delivered ribozyme in a phase I study: myeloid and lymphoid reconstitution in human immunodeficiency virus type-1-infected patients.

Amado RG, Mitsuyasu RT, Rosenblatt JD, Ngok FK, Bakker A, Cole S, Chorn N, Lin LS, Bristol G, Boyd MP, MacPherson JL, Fanning GC, Todd AV, Ely JA, Zack JA, Symonds GP.

Hum Gene Ther. 2004 Mar;15(3):251-62.

PMID:
15018734
46.

Critical steps in the implementation of hematopoietic progenitor-cell gene therapy using ribozyme vectors: a laboratory protocol.

Boyd MP, Ngok FK, Todd AV, Symonds GP, Macpherson JL, Amado RG.

Methods Mol Biol. 2004;252:599-616.

PMID:
15017083
47.

Clinical gene therapy research utilizing ribozymes: application to the treatment of HIV/AIDS.

Ngok FK, Mitsuyasu RT, Macpherson JL, Boyd MP, Symonds GP, Amado RG.

Methods Mol Biol. 2004;252:581-98.

PMID:
15017082
48.

Potential of acrylamide formation, sugars, and free asparagine in potatoes: a comparison of cultivars and farming systems.

Amrein TM, Bachmann S, Noti A, Biedermann M, Barbosa MF, Biedermann-Brem S, Grob K, Keiser A, Realini P, Escher F, Amadó R.

J Agric Food Chem. 2003 Aug 27;51(18):5556-60.

PMID:
12926914
49.

Gene therapy for HIV/AIDS: the potential for a new therapeutic regimen.

Fanning G, Amado R, Symonds G.

J Gene Med. 2003 Aug;5(8):645-53. Review.

PMID:
12898634
50.

Hepatocellular carcinoma screening in patients waiting for liver transplantation: a decision analytic model.

Saab S, Ly D, Nieto J, Kanwal F, Lu D, Raman S, Amado R, Nuesse B, Durazo F, Han S, Farmer DG, Ghobrial RM, Yersiz H, Chen P, Schwegel K, Goldstein LI, Tong M, Busuttil RW.

Liver Transpl. 2003 Jul;9(7):672-81.

Supplemental Content

Support Center